本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑 4 t! M& l; A2 u2 n7 _2 ^
& L/ [+ v8 y% r) R7 g
clinicaltrials上的三期临床链接* l" Y, ~6 m( {
8 D$ n& J6 M# uhttp://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn) x9 R1 x" N% k+ S. ]. L
' c5 E3 K w7 E中国参加临床实验的城市
# k4 N3 g9 |) m ^0 S
* {- |( o- m7 H' h. |China, Guangdong
7 j5 q/ r* N* M6 U s! C7 M6 B + C7 z) i8 P# k- ^2 E$ m' r) |
Guangzhou, Guangdong, China, 510515 2 m, @7 w/ B) n
' N" P4 }+ _- e. a8 q6 B# RGuangzhou, Guangdong, China, 510060 8 u1 r0 Q6 q2 `% e# ]$ y, D1 f
China, Jiangsu / q8 R3 ~8 y1 a: M
) {# ?. c# `' d e8 d' C
Nanjing, Jiangsu, China, 210009
: t0 y/ N) E% s1 C+ G
, N" Q1 o8 x# R! I$ v" _- @( l. ^; HNanjing, Jiangsu, China, 210002 8 Y- d) ~2 u$ j4 `4 j1 A
China, Shandong
6 k; @/ f- x5 Z) c% Q
1 K8 `, Z. p* x( Q) P: h5 @( HQingdao, Shandong, China, 266003 $ f8 A, F7 |' P' E& p& y8 Z
China
! f. s$ {( ?3 v d
: Z! W, O: l& X4 b4 SBeijing, China, 100021 : A# `$ o/ ~7 ]0 Q, @8 f
) r) e! h% I' @; |# }0 Y' ~
Beijing, China, 100071
1 K% @, T2 J a V9 Y$ x% } 6 Z+ e* c3 u& j0 C' w$ }) x
Changchun, China, 130021 , [' h4 T$ I* V
1 g9 E0 M# t! i8 @" m$ }4 o/ q
Chongqing, China, 400042
. j( B: f: K* c
; v) [% @" H3 j* {- wChongqing, China, 400038 ) d2 l3 }8 Y' q
* g4 `0 J1 H. t2 C5 ~- u
Fuzhou, China, 350014 & Z _0 `+ y a$ ?9 ~8 v$ R
- f6 O J; o$ ^: V, s0 A
Fuzhou, China, 350025
" M9 m% {, A0 ]' r 6 }3 P' f5 |9 l2 P) J1 j$ ^ ]. k
Ha'erbin, China, 150040
$ s+ q% f: [& k; Q" c: Y/ P; z/ }
2 b6 r h/ l/ {8 s; Q- Q9 ~Hanghzou, China, 310009
* a, U$ X7 ]- W! E( [( f( \
8 g F& y7 K, C, Z! GShanghai, China, 200001 6 u: S9 E' j) k# s, q* {% U
% J# ^4 K: Y6 ?- H3 N
Shanghai, China, 200030 0 k. E" U% P3 S, F& [4 f$ @1 b
+ k$ |& R* T$ @# ^
Tianjin, China / O9 C, n& d, f' j( f" n! \
. v8 Z: O" Y3 C* r# }, H9 z该实验已停止招募,重新开的临床请见临床专用贴。 |